Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the stock. The Goldman Sachs Group boosted their target price on shares of Myovant Sciences from $9.00 to $10.00 and gave the company a "neutral" rating in a research report on Thursday, July 28th. SVB Leerink upgraded shares of Myovant Sciences from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $12.00 to $23.00 in a research report on Tuesday, August 9th.
Myovant Sciences Price Performance
MYOV Stock opened at $18.23 on Friday. The company has a 50 day simple moving average of $13.54 and a 200 day simple moving average of $12.43. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -10.36 and a beta of 2.40. Myovant Sciences has a 1 year low of $7.67 and a 1 year high of $27.43.
Insiders Place Their Bets
In other Myovant Sciences news, General Counsel Matthew Lang sold 31,214 shares of the business's stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $18.23, for a total transaction of $569,031.22. Following the sale, the general counsel now directly owns 363,966 shares of the company's stock, valued at approximately $6,635,100.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Myovant Sciences news, General Counsel Matthew Lang sold 31,214 shares of the business's stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $18.23, for a total transaction of $569,031.22. Following the sale, the general counsel now directly owns 363,966 shares of the company's stock, valued at approximately $6,635,100.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ferreira Juan Camilo Arjona sold 2,755 shares of the business's stock in a transaction that occurred on Wednesday, July 6th. The stock was sold at an average price of $13.40, for a total transaction of $36,917.00. Following the sale, the insider now directly owns 255,992 shares in the company, valued at $3,430,292.80. The disclosure for this sale can be found here. Insiders have sold 41,310 shares of company stock valued at $702,389 in the last ninety days. 1.90% of the stock is currently owned by insiders.